Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
LUX-Breast Clinical Trial Programme Infographic thumb
 
Rating:00
view image larger
Related links:
LUX-Breast 3 Clinical Trial Infographic thumb
LUX-Breast 3 Clinical Trial Infographic
Read more >
Breast cancer backgrounder Thumbnail
Breast Cancer Backgrounder
Read more >

LUX-Breast Clinical Trial Programme Infographic

The LUX-Breast Clinical Trial Programme consists of three key clinical trials, investigating the safety and efficacy of afatinib* in patients with advanced/metastatic breast cancer. In total, an estimated 1020 patients will be enrolled into the LUX-Breast clinical trials in more than 300 locations in more than 30 countries.

If you are an investigator interested in becoming involved in one the studies and have potentially eligible patients, please visit ClinicalTrials.gov for more information about the trials.

*Afatinib is an investigational compound. Its safety and efficacy have not yet been fully established.

VIEW PREVIEW ADD TO SELECTION DOWNLOAD